

Performance in Initiating Clinical Trials Q4 2016-2017
70 day benchmark - first participant recruited HRA Approved Studies only

Ethics Committee Number	IRAS Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site confirmed by Sponsor	Date Site confirmed	Date Site Ready to Start	Date of First Patient Recruited	Target Met	Source of Delay	Comments
16/SC/0315	208760	Specific versus Generic Psychological therapy for children and young people with social anxiety disorder	12/07/2016	17/08/2016	17/08/2016	30/08/2016	30/08/2016	30/08/2016	07/09/2016	Yes		
16/SC/0363	205067	STEADFAST: Randomised, Double-blind, Placebo controlled, Multi-centre Trial to evaluate the efficacy and safety of TTP488-301 in patients with mild AD receiving Acetylcholinesterase inhibitors and/or Memantine	16/06/2016	20/10/2016	04/10/2016	21/10/2016	24/10/2016	26/10/2016	20/12/2016	Yes		
16/SC/0618	215934	Finding out Whether Virtual Reality May Help Individuals Feel Safer	18/11/2016	20/12/2016	13/12/2016	18/11/2016	21/12/2016	21/12/2016		No	Sponsor	Recruitment delay due to problems the sponsor is having with the Virtual Reality system
16/EE/0318	201898	A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression.	28/04/2016	17/01/2017	20/10/2016	17/01/2017	17/01/2017	24/01/2017	21/03/2017	Yes		
16/LO/1086	203002	A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a MonoAminergic antidepressant in Adults with Major Depressive Disorder	12/05/2016	06/02/2017	11/08/2016	31/01/2017	07/02/2017	17/02/2017		NA		
16/LO/1862	206680	The SlowMo Trial: A randomised controlled trial to evaluate the outcomes and mechanisms of a novel digital intervention for persecutory delusion	08/12/2016	26/03/2017	01/11/2016	06/04/2017	07/04/2017	07/04/2017		NA		

Performance in Initiating Clinical Trials Q4 2016-2017
 70 day benchmark - first participant recruited HRA Approved Studies only

16/SS/0115	206867	A Parallel-Group, Double-Blind, Long Term Safety and Efficacy Trial of MK-8931 (SCH900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease	20/09/2016	06/02/2017	24/08/2016	12/12/2016	12/12/2016	06/02/2017	06/03/2017	Yes		
------------	--------	---	------------	------------	------------	------------	------------	------------	------------	-----	--	--